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with neonatal cholestasis except for those with contraindica-
tions to liver biopsy. For that reason, we did not go through such
recruitment details in our article. None of the patients was
preterm and diagnoses were as described in the article. Causes
like alpha-1 antitrypsin, cystic ﬁbrosis and hypopituitarism were
not proven in our study population. In the validation group,
diagnoses like galactosemia, tyrosinemia, cytomegalovirus
induced hepatitis, biliary paucity and progressive familial
intrahepatic cholestasis (PFIC) were conﬁrmed by completing
the workup after being allocated earlier by the score as
non-BA. The PFIC patients, diagnosed in our study, were of type
3 with high gammaglutamyl transpeptidase (GGT) levels and
negative hepatic immunostaining for multidrug resistance
protein 3 and none were type PFIC1 or 2.
In accordance with our recent reports [2–4], earlier studies
[5–8] also reported that GGT levels differ signiﬁcantly and can
be used in discriminating BA from non-BA cases. So, we agree
with Pﬁster et al. that such difference should not be surprising.
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Open acScoring system in diagnosing biliary atresiaTo the Editor:
We read with great interest the article by El-Guindi et al. [1] who
propose a diagnostic scoring system for biliary atresia (BA),
including clinical, laboratory, ultrasonographic, and histopatholo-
gical parameters. They conclude that the scoring system could
discriminate BA from other causes of neonatal cholestasis with
a sensitivity, speciﬁcity and accuracy of 100%, 97.67%, and
98.83%, respectively, in the validation set. Thus, unnecessary
intraoperative cholangiography can be avoided in non-BA
patients. Although we appreciate their impressive ﬁndings, we
would raise a few issues.
First, it is known that hepatobiliary scintigraphy is an impor-
tant diagnostic modality for neonatal cholestasis and phenobar-
bital-enhanced hepatobiliary scintigraphy (PEHS) is considered
to be the most sensitive, non-invasive diagnostic method for BA
[2,3]. Two decades of experience at one tertiary centre demon-
strated that PEHS was 100% sensitive, 93.0% speciﬁc, and 94.6%
accurate in diagnosing BA [3]. Experience at another centre dem-
onstrated that 99mTc-EHIDA hepatobiliary scintigraphy in com-
bination with duodenal ﬂuid examination had both a sensitivity
and speciﬁcity of 100% [4]. Thus, hepatobiliary scintigraphy is a
non-invasive, safe, and accurate method for differential diagnosis
of BA and other causes of neonatal cholestasis [3,5]. Unfortu-
nately, the present study did not incorporate hepatobiliary scin-
tigraphy in obtaining a diagnostic score for BA. Thus, the lack of
this important imaging parameter might be responsible for the
false positivity in one of the patients who was wrongly diagnosed
with BA by the scoring system.
Second, although liver biopsy appears to be an important
diagnostic steps in the evaluation of BA, which may be safely per-
formed in small infants, it is undeniably an invasive procedure
associated with several adverse events and complications, such
as pain, bleeding, and even death [6]. Moreover, liver biopsy is
limited by sampling errors and observer variability, with possibil-
ity of omissions and false-positive or false-negative results. Thus,
liver biopsy should be avoided whenever possible, and hepatob-
iliary scintigraphy, especially PEHS, may take the place of liver
biopsy in the diagnosis of BA [3,5].
Finally, the sample size was relatively small in the present
study, and thus, validation of the scoring system in a large cohort
of patients is essential before the scoring system can be used in
clinical practice. We recommend that the scoring system beJournal of Hepatology 2014 vol. 61 j 1438–1452 1441
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Rui Dong⇑
Shan Zhengreassessed with or without incorporation of PEHS and with or
without removal of liver biopsy in a large study.
In addition, there seems an error in the manuscript; the
cut-off value may be ‘‘31.164’’, not ‘‘311.644’’ in Fig. 1C and D.
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Reply to: ‘‘Scoring system in diagnosing biliary atresia’’
To the Editor:
We appreciate the interest of Dong and Zheng in our recent study
[1]. Although hepatobiliary scintigraphy (HBS) is one of the most
sensitive methods for the diagnosis of biliary atresia (BA), it has a
low speciﬁcity (70.4%) as reported in a meta-analysis of 81 stud-
ies [2]. Sun et al. [3] reported a 13.3% (66/498) false positive rate
of HBS. They concluded that the excessive dependence on HBS
may contribute to the misdiagnosis of BA. Although HBS, showing
biliary excretion, excludes BA, non-excretion neither conﬁrms the
diagnosis of BA nor rules out the diagnosis of non-BA aetiologies
[4]. Oral phenobarbital can enhance the diagnostic performance
of HBS by re-examination one week later [5]; however, for the
potential delay in diagnosis it is not routinely practiced [6]. More-
over, the reported BA score speciﬁcity (97.67%) [1] cannot be
enhanced by HBS, which has a much lower speciﬁcity [2].
Liu and Huang [5] reported that if no bile was found in the
duodenal tube test (DTT), the drainage tube would be kept for
up to 72 h. In some cases, the duodenal ﬂuid changed from white
to yellow after several days or weeks. Therefore, persistent exam-
ination of the duodenal ﬂuid is very important. This also prolongs
the time of diagnosis and is not routinely performed. However,
DTT may have a special importance in situations where other
tests are not available [6].
An important concept of our BA score [1] is that it depends on
parameters that are an integral part of the workup and are
routinely performed for patients suffering neonatal cholestasis
(NC) whether suspected to be BA or non-BA. Contrarily, HBS
and DTT cannot be considered as such.
Dong and Zheng were encouraged by the article of Liu and
Huang [5] that reports a performance of combined HBS and
DTT of 100% sensitivity and 100% speciﬁcity. We read the article
with great interest but we found two major concerns. First,
recruitment of patients was selective as patients with certain
aetiologies were excluded from the study. This selectivity may
render the calculated speciﬁcity inaccurately a representative
one. Furthermore, it supports the concept that these procedures
are needed for selected patients. Second, the method of calculat-
ing the combined performance is not clear. According to their
results, 3 groups of patients can be discriminated: (1) Patients
having HBS with no excretion and DTT with no bile; (26 patients
with BA). (2) Patients having HBS with excretion and DTT with
bile; (41 patients with non-BA). (3) Patients having HBS with
no excretion and DTT with bile; (17 patients; 3 were BA and 14
were non-BA). These results can never, in any way, lead to a sen-
sitivity and speciﬁcity of 100%. It seems that Liu and Huang [5]
simply combined the sensitivity of one test (HBS) with the
speciﬁcity of the other (DTT) which is unreasonable.
Dong and Zheng, suggested that liver biopsy should be
avoided whenever possible. We disagree with this concept as
we believe that liver biopsy should be performed unless there
is a contraindication or when parents refuse the procedure. For
that, liver biopsy is considered as an integral part of the diagnos-
tic workup of NC patients and is strongly encouraged according
to ‘‘The Cholestasis Guideline Committee’’ of the NASPGN [7].
The aim of liver biopsy in NC is not only to evaluate the features
of biliary outﬂow obstruction but is also an essential tool in
revealing the aetiology of the liver disease, and in assessing the
ﬁbrosis stage which affects treatment policy. Such targets are
irreplaceable by HBS and DTT. For that, liver biopsy is generally
considered the ‘‘gold standard’’ compared to other diagnostic
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